Two Biotech Stocks to Buy Now for Massive Gains

There might be no better time to invest in biotech stocks. This industry is receiving a ton of attention now, from both government and media. Everyone is taking a closer look at drug prices.

We've been paying attention, too, and we know of a couple stocks that are ready to jump. We're going to share with you the top two biotech stocks to buy now.

Our proprietary Money Morning Stock VQScore™ system can quickly analyze thousands of investments and reveal the ones with the highest return potential. These biotech stocks have superb VQScores, meaning they are in prime position to give you big returns on your investment.

This has something to do with current events. U.S. President Donald Trump, in his latest State of the Union address, credited his administration for lowering the cost of pharmaceuticals. During the address, he cited a December 2018 figure that revealed the largest price decline in 46 years.

SESSIONS OUT: Trump's anti-marijuana AG is history, and the potential path to massive pot stock profits is wide open. Click here to learn about three of the best...

Though his comments sparked controversy, they were still promising for biotech firms, which had earlier been pressured by the president and lawmakers to lower prices. Where anticipation of price ceilings was enough to subdue many firms, the positive outlook now did the opposite.

Not only do these top biotech stocks to purchase now have strong breakout potential, they could also be targeted for takeovers in this industry ripe for consolidation.

One of these biotech stocks could earn you more than 150% profit...

Top Biotech Stocks to Buy Now, No. 2: Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is a Massachusetts-based biotech company focused on researching and developing small molecule drugs to treat liver diseases and viral infections.

Enanta had $325 million in cash per its last earnings report. This is equal to about 20% of its market cap, meaning it is highly stable financially, with significant room for growth.

Beyond having an excellent cash position, the company also has several drugs in the trial stage, meaning if one or more of these drugs is successful, the stock price will soar.

Six months ago, ENTA traded at over $125 per share, but this dropped when debates over pharmaceutical costs took center stage in Congress. Now, the 52-week low is $64.08, but share prices are back to over $100.

Analysts set a high price target of $130 for ENTA, which represents gains of 28.18% from today's price.

ENTA has a price/earnings (P/E) ratio of 24, slightly lower than the industry average of 32. The stock also has a high VQScore of 3.75, close to the "Buy Zone."

With three out of four analysts calling it a "buy," this is a biotech stock to get in on quickly. But its return can't quite match our next stock pick...

Top Biotech Stocks to Buy Now, No. 1: Corcept Therapeutics Inc.

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Speaking of stocks ready for a breakout, analysts expect Corcept Therapeutics Inc. (NASDAQ: CORT) to grow its profits by 66% in 2019.

Corcept develops drugs to help regulate the body's release of cortisol, otherwise known as the body's "alarm system" or "stress hormone." Fitting, because the Corcept stock might help you de-stress as well.

CORT has a very low P/E ratio of 10.58, signaling high profit potential once the stock is valued correctly.

The company's share price has fallen to $12.61 in the last year thanks to some mediocre company forecasts, but this only provides an excellent entry point for investment.

Fluctuations in the CORT share price will prove superficial once the pharmaceutical industry inevitably rears its head. CORT already made significant revenue advances in 2018, a spike of 58% year-over-year for Q4, and more is promised.

Its cash and investments at the end of Q4 2018 were $206.8 million, nearly doubling Q4 2017's $104 million.

But with its cash on hand and a 46% leap in research and development dollars from 2017-18, investors should expect continued growth in the CORT stock.

Analysts are also showing a high price target of $29, a 151.51% gain over the next year.

These 3 Stocks Are the Key to 2019's Greatest Profits

The 2018 midterm election was a turning point for the cannabis industry.

We expect nothing short of historic profits by the end of the year.

But not all pot stocks will hand you life-changing wins. In fact, often the companies making headlines are least likely to see the biggest gains.

These three stocks, on the other hand, are flying under the radar... for now. Each of them could see exponential stock price acceleration at any moment, and if you get in before that happens, you could turn a token stake into a lifetime of wealth.

I don't know of any other sector providing anywhere near this level of growth now.

Click here to learn more.

Follow Money Morning onFacebook, Twitter, and LinkedIn.